Most cases of acute pericarditis resolve within one to two weeks with anti-inflammatory medications, and treatment can often be managed entirely on an outpatient basis. The standard approach combines a high-dose anti-inflammatory drug with colchicine, a combination that more than halves the risk of the condition coming back. For the roughly 15 to 30 percent of people who experience a recurrence, additional therapies are available, including newer biologic medications approved specifically for stubborn cases.
How Pericarditis Is Diagnosed
Pericarditis is inflammation of the thin sac surrounding the heart. A diagnosis requires at least two of four clinical findings: sharp chest pain that improves when you sit up and lean forward (present in over 85 percent of cases), a scratchy sound heard through a stethoscope called a friction rub, characteristic changes on an ECG such as widespread ST elevation, or fluid accumulation around the heart visible on an echocardiogram. ECG changes and pericardial effusion each show up in about 60 percent of cases, while the friction rub is less common, occurring in roughly a third of patients.
Blood tests measuring inflammation markers, particularly C-reactive protein (CRP), help confirm the diagnosis and later guide decisions about tapering medication. These markers essentially tell your doctor whether the inflammation is still active or has settled down.
First-Line Treatment: NSAIDs Plus Colchicine
Anti-inflammatory drugs are the cornerstone of pericarditis treatment. The two most commonly used options are ibuprofen (400 to 800 mg three times daily) and aspirin (650 to 975 mg three to four times daily). Aspirin is generally preferred if you have any history of coronary artery disease, since ibuprofen can interfere with aspirin’s heart-protective effects. A stomach-protecting medication is typically prescribed alongside either drug to prevent irritation from the high doses involved.
For a first episode, you’ll take the full dose for one to two weeks, then gradually taper down as symptoms improve and inflammation markers normalize. The taper for ibuprofen is roughly 400 mg less per week; for aspirin, about 600 mg less per week. This gradual step-down is important. Stopping too quickly is one of the most common reasons pericarditis flares back up.
Colchicine is now added routinely alongside the anti-inflammatory drug. The typical dose is 0.5 mg twice daily if you weigh over 70 kg, or 0.5 mg once daily if you’re under 70 kg, continued for up to three months for a first episode. Adding colchicine increases the chance of remission within the first week and, critically, cuts the recurrence rate by more than half. The number needed to treat is just four, meaning that for every four people who take colchicine, one avoids a recurrence they otherwise would have had. That’s a strong benefit for a well-tolerated medication.
Why Corticosteroids Are Used Cautiously
Corticosteroids like prednisone produce fast, satisfying symptom relief, which makes them tempting. However, guidelines reserve them for patients who can’t tolerate or don’t respond to the NSAID-plus-colchicine combination. The reason: multiple observational studies have identified corticosteroid use as an independent risk factor for recurrence. The prevailing theory is that steroids suppress inflammation so broadly that the underlying process never fully resolves, setting the stage for a rebound once the drug is withdrawn.
Some newer research has challenged this view. One study found that low-dose prednisone produced recurrence rates statistically similar to those seen with NSAIDs (about 56 percent versus 64 percent, a difference that was not significant). Still, because the weight of evidence leans toward caution, most cardiologists treat corticosteroids as a second-line option and use them at the lowest effective dose with a very slow taper when they are necessary.
Treatment for Recurrent Pericarditis
Between 15 and 30 percent of people who have one episode of acute pericarditis will experience a recurrence, defined as a new flare after at least four to six months without symptoms. Recurrent episodes are treated with the same NSAID-plus-colchicine approach, but at longer durations: two to four weeks of full-dose anti-inflammatory therapy, with colchicine continued for up to six months.
When pericarditis keeps returning despite standard treatment, a class of biologic medications that block a specific inflammatory signaling molecule called interleukin-1 has changed the picture considerably. Rilonacept received FDA approval for recurrent pericarditis in March 2021, making it the first drug specifically approved for the condition. In clinical trials, it significantly reduced both the risk of recurrence and the number of flares. Another drug in the same class, anakinra, has shown similar benefits in registry data, reducing emergency visits, hospitalizations, and dependence on corticosteroids in patients whose pericarditis resisted colchicine. Both are given by injection, and they’re typically reserved for cases that have genuinely failed first-line therapy.
When Surgery Becomes Necessary
Surgery for pericarditis is uncommon and reserved for specific situations. Pericardiectomy, the partial or complete removal of the pericardial sac, is indicated for chronic constrictive pericarditis (where scarring and thickening of the pericardium restrict the heart’s ability to fill properly), for recurrent pericarditis that persists despite all available medical therapy, or rarely for structural complications. This is a major cardiac operation, and the decision to proceed happens only after a thorough course of medical treatment has been exhausted.
A separate, less invasive procedure called pericardiocentesis may be needed if a large pericardial effusion develops and compresses the heart. This involves draining fluid through a needle inserted near the chest wall, usually guided by ultrasound. It addresses the immediate danger of fluid buildup but doesn’t treat the underlying inflammation.
Activity Restrictions During Recovery
Physical activity restriction is a key part of treatment that’s easy to overlook. During active pericarditis, you should avoid exercise beyond light daily activities. Some experts recommend keeping your heart rate below 100 beats per minute until the episode has fully resolved. The concern is that vigorous activity increases heart rate and cardiac motion, which can worsen inflammation of the pericardial sac and delay healing.
For non-competitive exercisers, the general rule is to wait until symptoms have completely resolved, any fever is gone, there’s no remaining pericardial effusion, and blood inflammatory markers have returned to normal. Competitive athletes face stricter timelines. European guidelines recommend a minimum restriction of 30 days to 3 months depending on severity, with a full re-evaluation before returning to sports. If there’s any evidence of heart muscle involvement alongside the pericarditis, both U.S. and European guidelines recommend staying away from moderate to high-intensity exercise for 3 to 6 months.
What Recovery Looks Like
Acute pericarditis that responds to treatment typically resolves within four to six weeks. You’ll likely feel significant improvement within the first week once medication is started, but the full course of treatment, including the colchicine component, extends well beyond the point where you feel better. Stopping early is one of the strongest predictors of recurrence.
Pericarditis that lingers beyond six weeks without a symptom-free interval is classified as incessant. If it stretches past three months, it’s considered chronic. Recurrent pericarditis, by definition, involves a new flare after a documented period of remission lasting at least four to six months. Each of these patterns calls for progressively longer and more aggressive treatment strategies, which is why getting the initial episode treated fully, with proper tapering and the complete course of colchicine, matters so much for your long-term outcome.